It wasn’t expected to be a major State of the Union address—a final speech from a president in his last term, recounting achievements and expressing hope for the future. And then Obama made some news: “Let’s make America the country that cures cancer once and for all.” And to lead the administration’s effort, the president picked VP Joe Biden, who recently lost his son Beau to cancer, and who has said that finding a cure is one of his major life goals
ATCC, the premier global biological materials resource and standards organization, announces today that it licensed CRISPR/Cas9 gene editing technology from the Broad Institute of MIT and Harvard. ATCC plans to use the gene editing technology to develop a portfolio of new products and services to support basic and translational research.
Ligand Pharmaceuticals enters into a global license agreement with Emergent BioSolutions under which Emergent will use Ligand’s OmniRat, OmniMouse and OmniFlic technologies to discover fully human mono- and bispecific antibodies.
AUTM today released its highly regarded annual U.S. Licensing Activity Survey report for FY2014. Along with real world and human impact stories about technology transfer’s ability to improve lives and boost economies, the report analyzes licensing activities at U.S. universities, hospitals and research institutions, with data such as the following:
In a partnership announced today, MedImmune, AstraZeneca’s global biologics and development arm, and the University of California, San Francisco will initiate further exploration of disease biology, specifically delving into core underlying mechanisms in microbiome and regenerative medicine. With an emphasis on basic research and translational sciences, the organizations’ work will include working toward identifying biomarkers and understanding disease progression and the effects of biomarkers on clinical trial outcomes.
NEW YORK (GenomeWeb) – Qiagen said yesterday that it has inked a master collaboration for companion diagnostics codevelopment with Array BioPharma, the 15th pharma agreement of this type.
The way Health and Human Services Chief Technology Officer Susannah Fox sees it, the U.S. government totally missed the Internet boom and has been trying to catch up with ever since.
“I would say gently that the government was caught flat footed when the Internet came about,” she said
Advanced Accelerator Applications S.A. (NASDAQ: AAAP) announced an exclusive license agreement with Johns Hopkins University in Baltimore, Maryland to develop and market PSMA-SR6, a receptor ligand of Prostate-Specific Membrane Antigen (PSMA) for clinical therapeutic and diagnostic purposes. AAA will focus on developing this treatment and its companion diagnostic for prostate cancer through novel molecular nuclear medicine techniques similar to those implemented for the development of Lutathera and Somakit. Prostate cancer affects nearly 1 in 7 men during their lifetime worldwide.
AstraZeneca, along with its global biologics research and development arm, MedImmune, and Moderna Therapeutics today announced a new collaboration to discover, co-develop and co-commercialize messenger RNA (mRNA) therapeutic candidates for the treatment of a range of cancers. The collaboration is in addition to the agreement announced by the companies in 2013 to develop mRNA Therapeutics™ for the treatment of cardiovascular, metabolic and renal diseases as well as selected targets in oncology.
Leading global start up accelerator Dreamit today announced that it has renewed its partnerships with industry leaders Independence Blue Cross (Independence) and Penn Medicine to advance entrepreneurship and innovation in health care. The continued support follows significant upgrades to the Dreamit Health program announced earlier this year. The new model includes key changes designed to appeal to a broader range of entrepreneurs, including a no-cash/no-equity offer to draw later-stage companies and serial entrepreneurs who would not typically consider an accelerator program.
